News
MXCT
4.245
+5.34%
0.215
MAXCYTE, INC. MAXCYTE, INC. - MXCR - SIGNING OF STRATEGIC PLATFORM LICENSE
Reuters · 13h ago
Weekly Report: what happened at MXCT last week (0902-0906)?
Weekly Report · 09/09 09:05
MaxCyte Director Executes Options, Sells Shares
TipRanks · 09/07 21:09
MaxCyte Announces Participation in Bioprocessing Conference
TipRanks · 09/07 20:46
Weekly Report: what happened at MXCT last week (0826-0830)?
Weekly Report · 09/02 09:05
MaxCyte Director Executes Stock Options and Sells
TipRanks · 08/29 09:18
Weekly Report: what happened at MXCT last week (0819-0823)?
Weekly Report · 08/26 09:05
Weekly Report: what happened at MXCT last week (0812-0816)?
Weekly Report · 08/19 09:05
Weekly Report: what happened at MXCT last week (0805-0809)?
Weekly Report · 08/12 09:05
MAXCYTE INC: CONFIDENT WE WILL DELIVER OUR FULL YEAR GUIDANCE
Reuters · 08/07 06:12
Buy Rating Affirmed for MaxCyte on Strong SPL Revenue Growth and Solid Financial Position
TipRanks · 08/07 04:15
MaxCyte, Inc. Reports Financial Results for the Quarter Ended June 30, 2024
Press release · 08/07 02:12
MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q2 2024
Investorplace · 08/07 00:58
MaxCyte Updates Corporate Presentation for Investor Insight
TipRanks · 08/06 20:44
MAXCYTE INC -CONTINUES TO EXPECT FULL YEAR 2024 CORE BUSINESS REVENUE TO BE FLAT TO 5% GROWTH COMPARED TO 2023
Reuters · 08/06 20:05
MAXCYTE INC -QTRLY LOSS PER SHARE $0.09
Reuters · 08/06 20:05
Weekly Report: what happened at MXCT last week (0729-0802)?
Weekly Report · 08/05 09:05
MaxCyte Issues New Shares, Updates Capital
TipRanks · 08/01 15:59
MaxCyte Director Executes Stock Options and Sells Shares
TipRanks · 07/31 07:06
Weekly Report: what happened at MXCT last week (0722-0726)?
Weekly Report · 07/29 09:05
More
Webull provides a variety of real-time MXCT stock news. You can receive the latest news about Maxcyte through multiple platforms. This information may help you make smarter investment decisions.
About MXCT
MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance the discovery, development and commercialization of cell therapeutics, including cell and gene therapies, and to support cell-based research and development. It has developed and commercialized its proprietary Flow Electroporation technology, which is used by biopharmaceutical companies in the complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address this rapidly expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of cell-based medicines. The ExPERT family of products includes four instruments, which are known as the ATx, STx, GTx and VLx, as well as a portfolio of proprietary related disposables and consumables.